RSS

InflaRx

Biopharmaceutical company, InflaRx, has opened a new research facility in Ann Arbor, Michigan, USA, to further develop and extend the company’s complement system-based therapeutics. Read more

News

The FDA has accepted an IND application by biopharmaceutical company, InflaRx, which will enable the company to initiate a Phase IIb study evaluating the efficacy and safety of IFX-1 in patients with moderate or severe Hidradenitis Suppurativa. Read more

News